Perspective Study on Genetic Predispositions and Clinical Prognosis of Children and Adolescents With Malignant Brain Neoplasms in China

Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY

Primary malignant central nervous system (CNS) tumors are the second most common childhood malignancies. Amongst, medulloblastomas are the most common malignant brain tumor of childhood and occur primarily in the cerebellum. According to molecular characteristics, medulloblastomas were classified into four subtypes: WNT, SHH, Group3 and Group4 and different prognosis were noticed between subgroups. Several genetic predispositions related to clinical outcome were also discovered and might influence the treatment of medulloblastomas as novel pharmaceutical targets. This study aims to investigate genetic and cellular profiles of pediatric brain malignancies, mostly medulloblastomas, and other central nervous system tumor based on WGS, RNA-seq, single-cell sequencing and spatial transcriptomics. We also aim to investigate the correlation between genetic characteristics and clinical prognosis.

Eligibility
Participation Requirements
Sex: All
Maximum Age: 18
Healthy Volunteers: f
View:

• \- Children and adolescents aged between 0-18 years old, diagnosed with medulloblastoma or other malignant central nervous system tumors including glioma, ependymoma, germ cell tumors,tuberous sclerosis, neuronal and neuronoglial tumors, choroid plexus tumors, atypical teratoid/rhabdoid tumors, ependymoblastoma, and medulloepithelioma;

• Patients must be eligible for and receive tumor resection;

• Histological examination by institutional neuro-pathological evaluation must confirmed the diagnosis of brain malignancies;

• Participants consent with joining the current study and comply with follow-up visits;

• The patients must have no previous radiotherapy or chemotherapy other than corticosteroids.

Locations
Other Locations
China
Beijing Tiantan Hosiptal
RECRUITING
Beijing
Contact Information
Primary
Tao Jiang, MD
doctorjiangtt@163.com
+8613501306106
Backup
Yahui Zhao, MD
yahuii.zhao@hotmail.com
+8618519325917
Time Frame
Start Date: 2023-01-01
Estimated Completion Date: 2032-12-31
Participants
Target number of participants: 400
Sponsors
Leads: Beijing Tiantan Hospital

This content was sourced from clinicaltrials.gov